Related Experiment Video

Updated: Mar 17, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis

Soheil Tavakolpour1

  • 1Iran University of Medical Sciences, Tehran, Iran; Neuroscience Research center, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran.

Multiple Sclerosis and Related Disorders
|July 27, 2016
PubMed
Abstract

Insights

The Interleukin 7 receptor alpha (IL7RA) T244I polymorphism (rs6897932) is associated with a decreased risk of developing multiple sclerosis (MS). This finding suggests a genetic link to MS susceptibility, though further research is recommended.

Area of Science:

  • Neuroimmunology
  • Genetics
  • Epidemiology

Background:

  • Multiple sclerosis (MS) is a leading chronic inflammatory neurological disorder affecting young adults.
  • Both genetic and environmental factors contribute to MS risk.
  • The Interleukin 7 receptor alpha (IL7RA) gene, specifically the rs6897932 polymorphism, is investigated for its role in MS development.

Purpose of the Study:

  • To conduct a meta-analysis assessing the association between the IL7RA T244I polymorphism (rs6897932) and the risk of multiple sclerosis (MS).

Main Methods:

  • A systematic literature search was performed across PubMed, Scopus, and Google Scholar databases up to August 7, 2015.
  • Eleven eligible case-control studies, comprising 6752 MS cases and 7349 controls, were included in the meta-analysis.
  • Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using various genetic models (allelic, co-dominant, dominant, recessive) to evaluate the association.

Main Results:

  • The T allele of the IL7RA rs6897932 polymorphism was significantly associated with a reduced risk of MS (T vs. C: OR=0.84, 95% CI=0.77-0.92, P<0.001).
  • Significant associations were also found across co-dominant, dominant, and recessive genotype models, indicating a protective effect of the T allele.
  • Sensitivity analysis confirmed the reliability of the findings, and no publication bias was detected.

Conclusions:

  • The IL7RA T244I polymorphism (rs6897932) is associated with susceptibility to multiple sclerosis.
  • Further large-scale, well-designed studies are necessary to confirm this association and its clinical implications.
Keywords:
Interleukin 7 receptorMeta-analysisMultiple sclerosisPolymorphismsRs6897932

More Related Videos

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

31.5K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

945

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63